TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Mounjaro And Zepbound Power Eli Lilly's 54% Revenue Jump In Q3, Hikes 2025 Forecast

Benzinga Logo Benzinga By Vandana Singh
Mounjaro And Zepbound Power Eli Lilly's 54% Revenue Jump In Q3, Hikes 2025 Forecast

Eli Lilly reported Q3 revenue of $17.60 billion, a 54% year-over-year increase, driven by strong performance of weight loss drugs Mounjaro and Zepbound. The company raised its 2025 sales and earnings guidance, boosting investor confidence.

Insights
LLY   positive

Strong quarterly performance with 54% revenue growth, increased guidance, and significant revenue from weight loss drugs Mounjaro and Zepbound